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Letters to the Editorlymphadenectomy. According to the
literature, we think that different
maps based on histology (squamous
cell carcinoma or adenocarcinoma),
neoadjuvant therapy (performed or
not), and tumor site (upper thoracic,
middle thoracic, lower esophagus, or
esophagogastric junction) could be
made.
Moreover, we would like to under-
line the importance of the map of
nodal methastasis after neoadjuvant
therapy. In fact, the rate of esophageal
squamous cell carcinoma treated with
neoadjuvant therapy has increased
since the 1980s, and neoadjuvant
therapy followed by esophagectomy
currently is performed by most clini-
cians.5 A specific map for this therapy
pattern is worthwhile because the dis-
tribution of nodal metastasis could be
affected by preoperative treatment,4
and it requires a different map com-
pared with patients who undergo
only surgery.
This strategy could suggest the
most frequently involved lymph nodes
in each combination of the above-
mentioned variables, leading to an
improvement of the effectiveness of
surgery. Therefore, further studies
are needed to explore the reasonable-
ness of this idea, to exchange opinions
among research groups, and to gather
information for map construction.
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for their interest in our article.
Although controversies still remain
in the management of esophageal can-
cer, and neoadjuvant therapy has not
been widely conducted in China, it is
obvious that neoadjuvant therapy
plays an important role. Over the
past decade, treatment strategy has
changed a lot in our center. Between
2000 and 2004, the McKeown proce-
dure with a 3-field lymphadenectomy
was performed unselectively to all
patients with esophageal cancer. Since
2005, Ivor-Lewis esophagectomy
with 2-field lymphadenectomy has
been widely performed, and the
3-field lymphadenectomy procedure
was selectively applied on the basis
of ultrasound and computed tomogra-
phy information considering a higher
risk of complications. Although adju-
vant chemoradiotherapy after surgery
was routinely performed for advanced
cancers, the prognosis remains disap-
pointing in our experience. Therefore,
we also think neoadjuvant therapy
could improve the prognosis of
surgery.
As mentioned in our article, only
30 of 1491 patients with squamous
cell carcinoma (SCC) received che-
motherapy or radiotherapy before
surgery between 2006 and 2010 in
our center.1 There are several factors.
Surgeon’s preference may be the first
issue. The idea of neoadjuvantardiovascular Surgery c March 2013therapy for esophageal cancer has
not been widely accepted by surgeons
in China. Different pathologic pat-
terns from the West and increased
risk of complications may be 2 im-
portant factors influencing their treat-
ment decision making. Because most
patients with esophageal cancer came
from poor rural areas, heavy treat-
ment costs and inadequate medical
insurance would be the second rea-
son. However, in 2011, China spent
only 4.98% of its gross domestic
product on health care. On the other
hand, patients traditionally prefer to
receive resection when the cancer is
pathologically confirmed, so patients’
compliance for neoadjuvant therapy
would be another major factor. Fi-
nally, lack of prospective trials was
the most important problem. One lat-
est study showed that preoperative
chemoradiotherapy could improve
survival among patients with poten-
tially curable esophageal cancer.2
However, the results were limited be-
cause of the small sample of patients
with SCC. More randomized trials
with a larger sample for neoadjuvant
therapy for those with SCC are still
needed.
At present, the treatment strategy
for esophageal cancer is not uniform
in China, not only the administration
of neoadjuvant therapy but also
the choice of surgical approach, re-
construction route, and extent of
lymphadenectomy. Considering the
frustrating prognosis, efforts are nec-
essary to improve the survival. Ran-
domized clinical trials are being
performed in our center. Because
the left thoracic procedure is widely
performed in China,3 one study com-
paring the left and right thoracic
approaches (ClinicalTrials.gov iden-
tifier, NCT01047111) has enrolled
300 patients with middle and lower
esophageal cancer since 2010, and
follow-up information is being col-
lected. Another study comparing
3-field lymphadenectomy and 2-field
lymphadenectomy is ready to begin
and has been approved by the
Letters to the Editorinstitutional review board of Fudan
University Shanghai Cancer Center.
Prospective randomized research of
neoadjuvant therapy will be per-
formed soon. We are willing to share
the results with our colleagues
throughout the world and relate our
experience for the treatment of
esophageal cancer.
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SEROTONERGIC SYNDROME,
AND HEART TRANSPLANT
To the Editor:
Grubb and colleagues1 report a case
of a 60-year-old man with history of
nonischemic cardiomyopathy and
end-stage heart failure who underwent
placement of a left ventricular assist
device (LVAD) and replacement of
a mechanical aortic valve with a por-
cine prosthesis complicated by multi-
ple driveline infections. The heart
transplant was the last option. During
the operation, the authors reported
‘‘episodes of hypotension during the
extensive lysis of adhesions forThe Journal[LVAD] removal. Intermittent boluses
of phenylephrine were administered
to maintain a sufficient mean arterial
pressure.’’ Subsequently, a methylene
blue (MB) 1 mg/kg bolus followed by
continuous infusion of 0.5 mg/kg/hour
was administered. Postoperatively, the
patient presented signals of serotonin
syndrome, presumably a consequence
of an interaction between MB and an-
tidepressant medications.
This report has two crucial points:
the possibility of serotonin syndrome
triggered by the association MB and
antidepressants, and the routine use
of MB to handle vasoplegia in the mi-
lieu of heart transplant. Kofidis and
colleagues2 reported the first experi-
ence of vasoplegia treatment with
MB after heart transplant and pointed
out that this drug deserves attention
because of its catecholamine-saving
effect, thus preventing possible mal-
perfusion. Kofidis and colleagues’ re-
port is unique in the literature
regarding using MB to treat vasople-
gia associated with heart transplant.
In 2009, my colleagues and I pub-
lished an article3 discussing 15 years
of questions, answers, doubts, and cer-
tainties regarding MB for vasoplegic
syndrome treatment in heart surgery.
In summary, our report shared that
heparin and angiotensin-converting
enzyme inhibitors are risk factors; in
the recommended doses it is safe
(the lethal dose is 40 mg/kg); the use
of MB does not induce endothelial
dysfunction; the MB effect appears
in cases of nitric oxide up-regulation;
MB is not a vasoconstrictor—by
blocking the cyclic guanosine 3,
5-monophosphate (cGMP) pathway
it releases the cyclic adenosine
monophosphate (cAMP) pathway,
facilitating the norepinephrine vaso-
constrictor effect; the most used dos-
age is 2 mg/kg administered
intravenously as a bolus followed by
the same continuous infusion because
plasmatic concentrations strongly de-
cays in the first 40 minutes; and there
is a possible window of opportunity
for MB’s effectiveness.3of Thoracic and Cardiovascular SurgeTo circumvent the morbidity and
mortality associated with vasoplegic
syndrome Grubb and colleagues1 im-
plemented an intraoperative protocol
that includes administration of MB
for vasoplegic syndrome resistant to
vasopressor drugs. Because serotonin
syndrome only occurs in a small per-
centage of patients and is treatable
with benzodiazepines and supportive
care, and the possibility of serotonin
syndrome is less than the risk of un-
treated vasoplegia and potential end-
organ injury and graft loss, we have
continued to include MB in the
management of severe vasoplegic
syndrome.
I congratulate Grubb and colleagues
for reporting the association between
MB and antidepressants that may cause
serotonin syndrome. Although, to be
honest, as a proponent of the use of
MB4,5 the purpose of my letter is to
suggest Grubb and colleagues publish
their MB experience in heart transplant.
It would be a valuable contribution to
the cardiac surgery literature.
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Department of Surgery and Anatomy
Ribeir~ao Preto Faculty of Medicine
University of S~ao Paulo
Ribeir~ao Preto, S~ao Paulo, Brazil
References
1. Grubb KJ, Kennedy JL, Bergin JD, Groves DS,
Kern JA. The role of methylene blue in serotonin
syndrome following cardiac transplantation:
a case report and review of the literature. J Thorac
Cardiovasc Surg. 2012;144:e113-6.
2. Kofidis T, Str€uber M, Wilhelmi M, Anssar M,
Simon A, HarringerW, et al. Reversal of severe vas-
oplegia with single-dose methylene blue after heart
transplantation. J Thorac Cardiovasc Surg. 2001;
122:823-4.
3. Evora PR, Ribeiro PJ, Vicente WV, Reis CL,
Rodrigues AJ, Menardi AC, et al. Methylene blue
for vasoplegic syndrome treatment in heart surgery:
fifteen years of questions, answers, doubts and cer-
tainties. Rev Bras Cir Cardiovasc. 2009;24:279-88.
4. Andrade J, Batista M, Evora PR, Tavares JR,
Buffolo E, Ribeiro EE, et al. Methylene blue ad-
ministration in the treatment of the vasoplegic syn-
drome after cardiac surgery. Rev Bras Circ
Cardiovasc. 1996;11:207-14.
5. Evora PR, Ribeiro PJ, de Andrade JC. Methylene
blue administration in SIRS after cardiac opera-
tions. Ann Thorac Surg. 1997;63:1212-3.
http://dx.doi.org/10.1016/
j.jtcvs.2012.11.090ry c Volume 145, Number 3 897
